The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The role of physical fitness and PROs in frailty assessment for R/R multiple myeloma
In this video, Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, briefly discusses frailty assessment in relapsed/refractory (R/R) multiple myeloma and mentions the prognostic value of baseline physical fitness and patient-reported outcomes (PROs) in this patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Frailty assessment in the context of myeloma is very important because we need to provide individualized treatment decisions. So in the setting of newly diagnosed multiple myeloma, there is a wonderful frailty Index, which has been very well validated, which is the International Myeloma Working Group Frailty Index. Based on this index, we can actually identify three subpopulations: fit, frail, and intermediate...
Frailty assessment in the context of myeloma is very important because we need to provide individualized treatment decisions. So in the setting of newly diagnosed multiple myeloma, there is a wonderful frailty Index, which has been very well validated, which is the International Myeloma Working Group Frailty Index. Based on this index, we can actually identify three subpopulations: fit, frail, and intermediate. And we can provide tailored treatment based on this categorization. What we have done in this study is to actually see whether this prognostic index, this frailty index actually, might work also in the setting of relapsed/refractory multiple myeloma, and actually, it works very well. So, this is one of the very few pieces of evidence telling us that this frailty index also works in the setting of relapsed/refractory multiple myeloma. But on top of this, we have seen that if we had physical functioning at the baseline, so in conjunction with this frailty assessment, we can improve the accuracy of prediction of survival. So again, the message is that assessing physical fitness in this population might improve the accuracy of frailty assessment. So patient-reported outcomes, they provide, again, unique information that is not captured in the way we currently assess frailty in patients with myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
